1. COPANLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT B‐CELL LYMPHOMA (CHRONOS‐1). (June 2017) Authors: Dreyling, M.; Santoro, A.; Mollica, L.; Leppä, S.; Follows, G.A.; Lenz, G.; Kim, W.; Nagler, A.; Panayiotidis, P.; Demeter, J.; Özcan, M.; Kosinova, M.; Bouabdallah, K.; Morschhauser, F.; Stevens, D.A.; Trevarthen, D.; Giurescu, M.; Liu, L.; Koechert, K.; Peña, C. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 119 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. RAPID AND DURABLE RESPONSES WITH THE SYK/JAK INHIBITOR CERDULATINIB IN A PHASE 2 STUDY IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA—ALONE OR IN COMBINATION WITH RITUXIMAB. (12th June 2019) Authors: Smith, S.D.; Munoz, J.; Stevens, D.A.; Smith, S.M.; Feldman, T.A.; Ye, J.C.; de Vos, S.; Hess, B.T.; Miller, C.B.; Khatcheressian, J.L.; Birrell, M.R.; Leeds, J.M.; Coffey, G.P.; Conley, P.B.; Michelson, G.C.; Curnutte, J.T.; Hamlin, P.A. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 61 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. THE DUAL SYK/JAK INHIBITOR CERDULATINIB DEMONSTRATES RAPID TUMOR RESPONSES IN a PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL MALIGNANCIES. (June 2017) Authors: Hamlin, P.A.; Farber, C.M.; Fenske, T.S.; Khatcheressian, J.L.; Miller, C.B.; Munoz, J.; Patel, M.R.; Schreeder, M.T.; Smith, S.M.; Stevens, D.A.; Pandey, A.; Birrell, M.R.; Leeds, J.M.; Wang, Y.L.; Coffey, G.P.; Curnutte, J.T. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 74 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗